Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind study of nebulized BX004 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection
NL-OMON60192Phase 2Completed
- Sponsor
- BiomX
- Start
- Sep 2025
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) and Pseudomonas aeruginosa pulmonary infection comparing BX004 with Placebo (2 arms). Primary endpoint: Change from baseline in Pseudomonas aeruginosa CFU per gram of sputum at 8 weeks. Started Sep 2025; status: completed.
02
Drugs
BX004
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on NL-OMON60192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60192.